Pityriasis rosea-like eruption during treatment with imatinib mesylate: Description of 3 cases

被引:38
作者
Brazzelli, V
Prestinari, F
Roveda, E
Barbagallo, T
Bellani, E
Vassallo, C
Orlandi, E
Passamonti, F
Borroni, G
机构
[1] Univ Pavia, IRCCS, Policlin San Matteo, Dept Human & Hereditary Pathol,Inst Dermatol, I-27100 Pavia, Italy
[2] Univ Pavia, IRCCS, Policlin San Matteo, Inst Hematol, I-27100 Pavia, Italy
关键词
D O I
10.1016/j.jaad.2004.10.888
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of in IM-induced pityriasis rosea (PIZ)-like cutaneous eruption. Patients developed In erythematous slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions, reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.
引用
收藏
页码:S240 / S243
页数:4
相关论文
共 23 条
  • [1] ACKERMAN AB, 1997, HISTOLOGIC DIAGNOSIS, P623
  • [2] Cutaneous reactions to STI571
    Brouard, M
    Saurat, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (08) : 618 - 619
  • [3] Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia
    Brouard, MC
    Prins, C
    Mach-Pascual, S
    Saurat, JH
    [J]. DERMATOLOGY, 2001, 203 (01) : 57 - 59
  • [4] BUCKLEY C, 1996, BRIT J DERMATOL, V135, P652
  • [5] Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: A prospective case control study
    Chuh, AAT
    Chiu, SSS
    Peiris, JSM
    [J]. ACTA DERMATO-VENEREOLOGICA, 2001, 81 (04) : 289 - 290
  • [6] Mycosis fungoides-like reaction in a patient treated with Gleevec
    Clark, SH
    Duvic, M
    Prietol, VG
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2003, 30 (04) : 279 - 281
  • [7] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
    Druker, BJ
    Sawyers, CL
    Kantarjian, H
    Resta, DJ
    Reese, SF
    Ford, JM
    Capdeville, R
    Talpaz, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042
  • [8] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker, BJ
    Talpaz, M
    Resta, DJ
    Peng, B
    Buchdunger, E
    Ford, JM
    Lydon, NB
    Kantarjian, H
    Capdeville, R
    Ohno-Jones, S
    Sawyers, CL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
  • [9] Mechanisms of disease - The biology of chronic myeloid leukemia
    Faderl, S
    Talpaz, M
    Estrov, Z
    O'Brien, S
    Kurzrock, R
    Kantarjian, HM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) : 164 - 172
  • [10] Hasan S, 2003, J NATL MED ASSOC, V95, P722